LACTOLOGY FOUNDATION

Mepenzolate (ATC A03AB12) is a quaternary ammonium antimuscarinic used for functional gastrointestinal disorders and peptic ulcer disease, but its use is now limited and largely historical in many countries. As with other anticholinergics, lactation risk is driven mainly by systemic exposure in the mother and the theoretical impact on milk production and infant anticholinergic effects.medpedia.framar+6

Pharmacological group and agents

Drugs in ATC class A03AB12 comprise the antimuscarinic agent mepenzolate, classified among synthetic anticholinergics, quaternary ammonium compounds for functional gastrointestinal disorders. These agents act primarily in the gastrointestinal tract to reduce motility and secretion, and mepenzolate is the specific representative of this sub-subgroup.drugbank+4

Mechanism of action

Mepenzolate is a postganglionic parasympathetic inhibitor that competitively blocks muscarinic acetylcholine receptors in the gastrointestinal tract. By antagonizing muscarinic receptors, it decreases gastric acid and pepsin secretion and suppresses spontaneous colonic contractions, leading to reduced motility and spasm.wikipedia+3

Indications and clinical use

Historically, mepenzolate was approved as adjunctive therapy in the treatment of peptic ulcer disease by decreasing gastric acid production and bowel contractions. It has not been shown to improve ulcer healing or prevent recurrence or complications, and in many settings it has been discontinued or is rarely used in contemporary practice.mayoclinic+4

Dosage and administration

Clinical references describe adult oral doses of mepenzolate bromide of 25–50 mg four times daily, typically taken with meals and at bedtime for peptic ulcer. Therapy is prescription-only, and product-specific dosing and duration should be individualized by a prescriber, particularly given the limited evidence for efficacy and the potential for anticholinergic adverse effects.wikidoc+3

Contraindications and precautions

Local Bulgarian pharmacological information notes that mepenzolate should not be used in patients with hypersensitivity to the active substance or excipients. By class analogy with other antimuscarinics, important clinical precautions include use in patients with narrow-angle glaucoma, prostatic hypertrophy with urinary retention risk, obstructive uropathy, paralytic ileus, severe ulcerative colitis, and certain tachyarrhythmias.ncbi.nlm.nih+3

Adverse effects and toxicity

Common adverse reactions to mepenzolate include typical anticholinergic effects such as dry mouth, blurred vision, constipation, urinary retention, and dizziness or drowsiness. Overdose or high exposure can lead to a full anticholinergic syndrome (hyperthermia, tachycardia, urinary retention, delirium), and caution is advised in older adults and those with cardiovascular or cognitive vulnerabilities.patents.google+4

Drug interactions and toxicodynamic concerns

The Framar interaction module reports a large number of potential interactions for mepenzolate, including several with high clinical significance. As with other anticholinergics, additive anticholinergic toxicity can occur with concomitant use of tricyclic antidepressants, first-generation antihistamines, antiparkinsonian anticholinergics, phenothiazines, and other muscarinic antagonists.drugcentral+3

Use in pregnancy

There are limited contemporary data on mepenzolate use in pregnancy, and its historical use predates modern regulatory standards. In the absence of robust human data and given the availability of safer alternatives for functional gastrointestinal disorders and peptic ulcer disease, most authorities would prefer agents with established safety profiles in pregnancy.kellymom+5

Lactation: transfer into milk

No specific LactMed or detailed quantitative data were identified for mepenzolate, but general principles for medications in breastfeeding suggest that quaternary ammonium anticholinergics have limited oral bioavailability and poor central penetration. Nonetheless, it is generally accepted that all medications transfer into human milk to some degree, and even small amounts of potent anticholinergics could theoretically cause gastrointestinal or neurological effects in the breastfed infant.mothertobaby+5

Lactation: potential risks for the infant

Potential infant risks with maternal mepenzolate therapy include anticholinergic effects such as decreased gastrointestinal motility, constipation, urinary retention, and, at higher exposures, possible irritability, sedation, or feeding difficulties. Premature infants and neonates with comorbidities have reduced capacity to metabolize and excrete drugs and would warrant particularly cautious risk–benefit assessment.lllusa+4

Lactation: potential effects on milk production

Anticholinergic drugs can theoretically interfere with prolactin release and reduce milk production, although clinically significant suppression is uncommon and more likely with centrally acting agents. Given that mepenzolate is a peripherally acting quaternary ammonium compound, any impact on milk supply is probably modest, but susceptible mothers or those with borderline milk production may still experience decreased supply.kellymom+2

Lactation: risk assessment and clinical recommendations

Current lactation resources emphasize that the vast majority of medications are compatible with breastfeeding and that stopping breastfeeding is rarely necessary, particularly when safer alternatives exist. For quaternary ammonium anticholinergics such as mepenzolate, use during breastfeeding should generally be avoided when non-anticholinergic alternatives can effectively treat the underlying gastrointestinal condition, especially in early postpartum and in preterm or medically fragile infants.mothertobaby+2

Practical management in breastfeeding women

When a breastfeeding mother requires therapy for functional gastrointestinal disorders or acid-related disease, clinicians should preferentially select medications with well-characterized lactation safety profiles and minimal anticholinergic effects. If mepenzolate is deemed necessary due to lack of alternatives or special indications, the lowest effective dose and shortest possible duration should be used, with close monitoring of the infant for feeding difficulties, constipation, poor weight gain, or unusual behavior.mayoclinic+3

Professional resources and counselling

Healthcare professionals should consult specialized resources such as LactMed, Medications and Mothers’ Milk, and national or regional teratology information services when evaluating mepenzolate or related anticholinergics in lactating patients. Parents should be advised not to discontinue breastfeeding without individualized counselling, and to report any signs of infant intolerance or maternal lactation problems promptly.youtubelllusa+2